Company News: Gilead Sciences, Cubist Pharmaceuticals and Calixa Therapeutics

Share this article:
Gilead Sciences said that it will likely end development of darusentan, a once promising endothelin receptor antagonist for treating resistant hypertension, because the agent did not achieve its co-primary endpoints in a phase III trial.

Cubist Pharmaceuticals said it plans to acquire privately held Calixa Therapeutics for $92.5 million in cash and up to $310 million in milestone payments. In the deal, expected to close by year's end, Cubist would obtain Calixa's rights to develop and commercialize the firm's Phase 2 antibiotic CXA-201, which is intended to treat common, serious Gram-negative infections.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.